RO7269162 clinical trials

A Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD)

This study is for people aged 60-85 at risk of Alzheimer's or with very early memory problems. It tests a new potential medicine, RO7269162, to see if it's safe and affects the disease. Participants will receive the new medicine or a dummy treatment, with regular check-ups.